Added to YB: 2026-06-18
Pitch date: 2026-06-15
NGEN [neutral]
NervGen Pharma Corp.
Author Info
Company Info
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.
Market Cap
$397.0M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.35
P/E
-8.75
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
NervGen: Chasing Ozempic for the Nervous System.
NGEN (overview): Clinical-stage biotech; NVG-291 peptide jams CSPG/PTPσ 'brake,' potentially regenerating CNS nerves across spinal cord injury, stroke, aging. Targets ~$11.5B→$32B nerve repair market w/ no existing regen drug. 'Ozempic for nervous system' platform bet. Risks: one peptide, one patent (Case Western), early/small human data, awaiting Phase 3.
Read full article (7 min)